26
Special Populations
Table 6. Vaccination of Persons With Chronic Inflammatory
Diseases on Immunosuppressive Medications
Recommendation
(Strength, Evidence Quality)
Vaccine
Planned
Immunosuppression
Low-Level
Immunosuppression
a
High-Level
Immunosuppression
a
H influenzae
type b
conjugate
U (SR-M) U (SR-L) U (SR-L)
Hepatitis A U (SR-M) U (SR-L) U (SR-L)
Hepatitis B U (SR-M) U (SR-L) U (SR-L)
DTaP, Td,
Tdap
U (SR-M) U (SR-L) U (SR-L)
HPV U: age 11-26 y (SR-M) U: age 11-26 y (SR-L) U: age 11-26 y (SR-VL)
Influenza,
inactivated
U (SR-M) U (SR-M) U (SR-M)
Influenza, live
attenuated
X (WR-VL) X (WR-VL) X (WR-VL)
MMR, live Ub (SR-M) X (WR-VL) X (WR-VL)
MMRV, live Ub (SR-L) X (WR-VL) X (SR-VL)
Meningococcal
conjugate
U (SR-M) U (SR-M) U (SR-L)
Pneumococcal
conjugate
(PCV13)
Rc (SR-M) U: age <6 y (SR-L)
R: age ≥6 yc (SR-VL)
U: age <6 y (SR-L)
R: age ≥6 yc (SR-VL)
Pneumococcal
polysaccharide
(PPSV23)
R: age ≥2 y (SR-L) R: age ≥2 y (SR-L) R: age ≥2 y (SR-VL)
Poliovirus,
inactivated
U (SR-M) U (SR-M) U (SR-L)
Rotavirus, live U (SR-M) X (WR-VL) X (WR-VL)
Varicella, live Ub (SR-M) Xd (WR-VL) X (SR-M)
Zoster, live R: age 50-59 y*
(WR-L)
U: age ≥60 y (SR-L)
R: age 50-59 y*
(WR-VL)
U: age ≥60 y (SR-VL)
X (WR-VL)
